Scientists gather samples on the ocean floor.
Credit: Roger Linington.
There’s nothing new about looking to nature to cure disease – we’ve been doing it for thousands of years, with good results. (Two recent examples: The active ingredient in aspirin was first identified in the bark of the willow tree. And we have the Pacific yew tree to thank for one of the strongest anti-cancer drugs out there, Taxol.)

What’s different about the work being done at the UC Santa Cruz Chemical Screening Center is that it a) looks to a largely unexplored medical resource: the ocean, and b) uses robots, rather than “forlorn-looking grad students” (to quote Center director Scott Lokey) to run the tests.

Here’s a video I shot of one of those robots in action, with Lokey narrating.

One thing that didn’t make it into the piece is that these researchers — including Lokey and Roger Linington — aren’t just studying every disease they can think of. They focus on the diseases that commercial drug companies tend to neglect because there’s so little profit in treating them – things like African sleeping sickness and cholera. So far, they’re seeing progress on both, as well as breast cancer.

Listen to the Medicine from the Ocean Floor radio report online and check out images from this story in an online slideshow.

36.97728 -122.05366

  • Pingback: Reporter’s Notes: Medicine from the Ocean Floor | Breast Cancer Center()

  • Anonymous

    Chronic cerebrospinal venous insufficiency (CCSVI), or the pathological restriction of venous vessel discharge from the CNS has been proposed by Zamboni, et al, as having a correlative relationship to Multiple Sclerosis. From a clinical perspective, it has been demonstrated that the narrowed jugular veins in an MS patient, once widened, do affect the presenting symptoms of MS and the overall health of the patient. It has also been noted that these same veins once treated, restenose after a time in the majority of cases. Why the veins restenose is speculative. One insight, developed through practical observation, suggests that there are gaps in the therapy protocol as it is currently practiced. In general, CCSVI therapy has focused on directly treating the venous system and the stenosed veins. Several other factors that would naturally affect vein recovery have received much less consideration. As to treatment for CCSVI, it should be noted that no meaningful aftercare protocol based on evidence has been considered by the main proponents of the ‘liberation’ therapy (neck venoplasty). In fact, in all of the clinics or hospitals examined for this study, patients weren’t required to stay in the clinical setting any longer than a few hours post-procedure in most cases. Even though it has been observed to be therapeutically useful by some of the main early practitioners of the ‘liberation’ therapy, follow-up, supportive care for recovering patients post-operatively has not seriously been considered to be part of the treatment protocol. To date, follow-up care has primarily centered on when vein re-imaging should be done post-venoplasty. The fact is, by that time, most patients have restenosed (or partially restenosed) and the follow-up Doppler testing is simply detecting restenosis and retrograde flow in veins that are very much deteriorated due to scarring left by the initial procedure. This article discusses a variable approach as to a combination of safe and effective interventional therapies that have been observed to result in enduring venous drainage of the CNS to offset the destructive effects of inflammation and neurodegeneration, and to regenerate disease damaged tissue.
    As stated, it has been observed that a number of presenting symptoms of MS almost completely vanish as soon as the jugulars are widened and the flows equalize in most MS patients. Where a small number of MS patients have received no immediate benefit from the ‘liberation’ procedure, flows in subject samples have been shown not to have equalized post-procedure in these patients and therefore even a very small retrograde blood flow back to the CNS can offset the therapeutic benefits. Furthermore once the obstructed veins are further examined for hemodynamic obstruction and widened at the point of occlusion in those patients to allow full drainage, the presenting symptoms of MS retreat. This noted observation along with the large number of MS patients who have CCSVI establish a clear association of vein disease with MS, although it is clearly not the disease ‘trigger’.For more information please visit


Amy Standen

Amy Standen (@amystanden) is co-host of #TheLeapPodcast (subscribe on iTunes or Stitcher!) and host of KQED and PBSDigital Studios' science video series, Deep Look.  Her science radio stories appear on KQED and NPR. Email her at

Sponsored by

Become a KQED sponsor